Enterprise Value
168.3M
Cash
236.8M
Avg Qtr Burn
-24.96M
Short % of Float
16.92%
Insider Ownership
5.01%
Institutional Own.
73.63%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma, Diffuse large B cell lymphoma, Cancer | Approved Quarterly sales | |
Phase 3 Data readout | ||
XPOVIO (Selinexor) (XPO1 inhibitor) Details Cancer, Endometrial cancer | Phase 3 Data readout | |
Eltanexor Details Colorectal cancer , Prostate cancer, Multiple myeloma, Myelodysplastic syndrome | Phase 2 Update | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Glioblastoma | Failed Discontinued | |
XPOVIO (Selinexor) Details COVID-19 | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) (in combination with rituximab-gemcitabine-dexamethasone-platinum (R-GDP)) Details Diffuse large B cell lymphoma | Failed Discontinued | |
KPT-9274 (PAK4 and NAMPT inhibitor) Details Solid tumor/s | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Rare diseases, Liposarcoma, Cancer | Failed Discontinued | |
XPOVIO (Selinexor) (XPO1 inhibitor) Details Multiple myeloma | Failed Discontinued |